Tag: Atara Biotherapeutics
December 17, 2018
Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma
Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral... November 30, 2018
Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
November 19, 2018
Atara Biotherapeutics Releases Published Clinical Results
The results are for a Phase 1 clinical study of ATA190, an autologous EBV-specific T-cell immunotherapy in development for multiple... November 19, 2018
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement
Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral... September 6, 2018
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral... February 28, 2018
Atara Biotherapeutics Announces Proposed Offering of Common Stock
Atara Biotherapeutics (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases,... February 27, 2018
